The palynziq market research report is one of a series of new reports that provides palynziq market statistics, including palynziq industry global market size, regional shares, competitors with a palynziq market share, detailed palynziq market segments, market trends and opportunities, and any further data you may need to thrive in the palynziq industry. This palynziq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to emerging therapies, increased genetic testing, expansion into new markets, a focus on patient-centric care, collaborations, and partnerships. Major trends in the forecast period include innovative enzyme therapy, clinical trial successes, pediatric considerations, a focus on reimbursement policies, and telehealth integration.
The increasing awareness of genetic disorders is expected to drive the growth of the Palynziq market in the future. Genetic disorders encompass a wide range of conditions caused by abnormalities in an individual’s DNA, which can range from single-gene mutations to complex chromosomal changes. The rising awareness is due to factors such as improved access to genetic testing through advances in genomic sequencing, the availability of affordable at-home DNA testing kits, global health campaigns promoting early diagnosis and intervention, and the inclusion of genetic education in healthcare systems. As awareness of these disorders grows, both patients and healthcare providers are becoming more informed about treatment options such as Palynziq, leading to an increase in demand. For example, in June 2022, a report by RARE-X, an Australia-based patient support platform, indicated that there were over 10,800 rare diseases, including both genetic and non-genetic conditions. This growing awareness is helping to drive demand for treatments such as Palynziq.
A significant trend in the Palynziq market is the investment in post-marketing surveillance (PMS) studies to monitor the safety of the drug and ensure regulatory compliance, while also building trust with healthcare providers and patients. These studies aim to improve treatment outcomes, patient quality of life, and overall therapeutic success. For instance, in June 2022, BioMarin Pharmaceutical initiated a 10-year global observational study to further assess the safety profile of Palynziq, particularly focusing on hypersensitivity reactions, long-term safety, tolerability, and the effectiveness of additional risk minimization strategies. This effort aims to enhance the safety management of Palynziq and optimize its therapeutic results for patients with phenylketonuria.
In November 2023, Elliott Investment Management L.P., a US-based investment firm, acquired a $1 billion stake in BioMarin Pharmaceutical. This move reflects a period of transition and strategic reassessment for BioMarin, driven by leadership changes within the company and the influence of external investors. BioMarin, a biotechnology company specializing in therapies for rare and genetic diseases, including Palynziq, is positioning itself for future growth with this investor engagement.
The key company operating in the palynziq market is BioMarin Pharmaceutical Inc.
North America was the largest region in the palynziq market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in palynziq report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the palynziq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Palynziq is the brand name for pegvaliase-pqpz, a biologic medication used in the treatment of phenylketonuria (PKU), a rare genetic disorder that impairs the body's ability to metabolize phenylalanine, an amino acid found in food. Palynziq provides an enzyme that helps break down phenylalanine in the blood, thereby lowering its levels and preventing neurological damage caused by elevated phenylalanine concentrations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Palynziq include phenylketonuria (PKU) and other related metabolic disorders. PKU is a genetic condition marked by the inability to process phenylalanine due to a deficiency of the enzyme phenylalanine hydroxylase. Palynziq is distributed through various channels, including pharmacies and online pharmacies, and is used by multiple end users such as hospitals, specialty clinics, and home care settings.
The palynziq market consists of sales of pre-filled syringes, treatment kits, multi-dose vials, patient kits (with accessories), and unit dose packs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to emerging therapies, increased genetic testing, expansion into new markets, a focus on patient-centric care, collaborations, and partnerships. Major trends in the forecast period include innovative enzyme therapy, clinical trial successes, pediatric considerations, a focus on reimbursement policies, and telehealth integration.
The increasing awareness of genetic disorders is expected to drive the growth of the Palynziq market in the future. Genetic disorders encompass a wide range of conditions caused by abnormalities in an individual’s DNA, which can range from single-gene mutations to complex chromosomal changes. The rising awareness is due to factors such as improved access to genetic testing through advances in genomic sequencing, the availability of affordable at-home DNA testing kits, global health campaigns promoting early diagnosis and intervention, and the inclusion of genetic education in healthcare systems. As awareness of these disorders grows, both patients and healthcare providers are becoming more informed about treatment options such as Palynziq, leading to an increase in demand. For example, in June 2022, a report by RARE-X, an Australia-based patient support platform, indicated that there were over 10,800 rare diseases, including both genetic and non-genetic conditions. This growing awareness is helping to drive demand for treatments such as Palynziq.
A significant trend in the Palynziq market is the investment in post-marketing surveillance (PMS) studies to monitor the safety of the drug and ensure regulatory compliance, while also building trust with healthcare providers and patients. These studies aim to improve treatment outcomes, patient quality of life, and overall therapeutic success. For instance, in June 2022, BioMarin Pharmaceutical initiated a 10-year global observational study to further assess the safety profile of Palynziq, particularly focusing on hypersensitivity reactions, long-term safety, tolerability, and the effectiveness of additional risk minimization strategies. This effort aims to enhance the safety management of Palynziq and optimize its therapeutic results for patients with phenylketonuria.
In November 2023, Elliott Investment Management L.P., a US-based investment firm, acquired a $1 billion stake in BioMarin Pharmaceutical. This move reflects a period of transition and strategic reassessment for BioMarin, driven by leadership changes within the company and the influence of external investors. BioMarin, a biotechnology company specializing in therapies for rare and genetic diseases, including Palynziq, is positioning itself for future growth with this investor engagement.
The key company operating in the palynziq market is BioMarin Pharmaceutical Inc.
North America was the largest region in the palynziq market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in palynziq report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the palynziq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Palynziq is the brand name for pegvaliase-pqpz, a biologic medication used in the treatment of phenylketonuria (PKU), a rare genetic disorder that impairs the body's ability to metabolize phenylalanine, an amino acid found in food. Palynziq provides an enzyme that helps break down phenylalanine in the blood, thereby lowering its levels and preventing neurological damage caused by elevated phenylalanine concentrations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Palynziq include phenylketonuria (PKU) and other related metabolic disorders. PKU is a genetic condition marked by the inability to process phenylalanine due to a deficiency of the enzyme phenylalanine hydroxylase. Palynziq is distributed through various channels, including pharmacies and online pharmacies, and is used by multiple end users such as hospitals, specialty clinics, and home care settings.
The palynziq market consists of sales of pre-filled syringes, treatment kits, multi-dose vials, patient kits (with accessories), and unit dose packs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Palynziq Market Characteristics4. Palynziq Market Trends And Strategies5. Palynziq Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Palynziq Pricing Analysis & Forecasts30. Global Palynziq Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Palynziq Market32. Recent Developments In The Palynziq Market
3. Palynziq Market Biologic Drug Characteristics
6. Global Palynziq Growth Analysis And Strategic Analysis Framework
8. Palynziq Market Segmentation
9. Global Palynziq Epidemiology Of Clinical Indications
10. Palynziq Market Regional And Country Analysis
11. Asia-Pacific Palynziq Market
12. China Palynziq Market
13. India Palynziq Market
14. Japan Palynziq Market
15. Australia Palynziq Market
16. South Korea Palynziq Market
17. Western Europe Palynziq Market
18. UK Palynziq Market
19. Germany Palynziq Market
20. France Palynziq Market
21. Eastern Europe Palynziq Market
22. North America Palynziq Market
23. USA Palynziq Market
24. Canada Palynziq Market
25. South America Palynziq Market
26. Middle East Palynziq Market
27. Africa Palynziq Market
28. Palynziq Market Competitive Landscape And Company Profiles
29. Global Palynziq Market Pipeline Analysis
33. Palynziq Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Palynziq Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on palynziq market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for palynziq ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The palynziq market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Phenylketonuria (PKU); Other Related Metabolic Disorders2) By Distribution Channel: Pharmacies; Online Pharmacies
3) By End User: Hospitals; Specialty Clinics; Home Care Settings
Key Companies Profiled: BioMarin Pharmaceutical Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- BioMarin Pharmaceutical Inc.
